glp-1 agonists tirzepatide How medications are transforming diabetes and weight loss treatment GLP-1 use tripled among non-diabetics,

Tirzepatide is a dual-agonist , activating two hormonal pathways: GLP-1 appetite control GIP enhanced fat metabolism + energy regulation Together, these pathways create: Stronger appetite suppression Faster fat oxidation Greater weight-loss efficiency Better metabolic flexibility Its the next evolution of medical weight loss

Documented research applications include: Photoprotection & UV Damage Research Studies have explored MT1s potential to stimulate melanin production ahead of UV exposure, with afamelanotide gaining regulatory approval in several countries (including the EU and Australia) under the brand name Scenesse for the management of Erythropoietic Protoporphyria (EPP)

doi: 53 NHS (2018) Non-alcoholic fatty liver disease (NAFLD)

Check-in ready Your care team can review next steps

Novo Nordisk and Eli Lilly hold uniquely dominant positions, with competition intensifying as pharmaceutical challengers increase investment across all GLP-1 ecosystem layers